Литва - литовский - SMCA (Valstybinė vaistų kontrolės tarnyba)

b.braun melsungen ag - deksmedetomidinas - koncentratas infuziniam tirpalui - 100 µg/ml - dexmedetomidine

Литва - литовский - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - deksmedetomidinas - koncentratas infuziniam tirpalui - 100 µg/ml - dexmedetomidine

Европейский союз - литовский - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioedema, paveldima - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Европейский союз - литовский - EMA (European Medicines Agency)

paion deutschland gmbh - remimazolam besilate - sąmoningas sedavimas - psicholeptikai - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Литва - литовский - SMCA (Valstybinė vaistų kontrolės tarnyba)

fresenius kabi polska sp.z.o.o. - deksmedetomidinas - koncentratas infuziniam tirpalui - 100 µg/ml - dexmedetomidine

Европейский союз - литовский - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Европейский союз - литовский - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - imunosupresantai - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Европейский союз - литовский - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Европейский союз - литовский - EMA (European Medicines Agency)

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Европейский союз - литовский - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antinavikiniai vaistai - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.